ImmuneXcite currently has discovery programs across a range of tumor targets.
The company’s proprietary mAbXcite product engine provides:
- A transformative approach to treating cancer
- Ability to treat a wide range of solid and liquid tumors
- Does not compete with checkpoint inhibitors, which are being explored as potential combination therapies to further enhance mAbXcite’s overall effectiveness
- A simple targeted product that may not require chronic administration
- Straightforward development and manufacturing